Skip to content

Treatment of varicose veins

Comparison of the results of concomitant radiofrequency ablation and sclerotherapy for varicose veins versus treatment in two different sessions

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017030916473N8
Enrollment
80
Registered
2017-03-14
Start date
2016-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Varicose veins. Varicose veins of lower extremities

Interventions

The control group will be undergone varicose vein radiofrequency ablation in one session and sclerotherapy will be deferred for another session two weeks later.
Intervention 1: The intervention group will be undergone the standard RFA procedure and sclerotherapy of the smaller venous territories at the same session. Intervention 2: The control group will be u
Treatment - Surgery
The intervention group will be undergone the standard RFA procedure and sclerotherapy of the smaller venous territories at the same session.

Sponsors

Tabriz University Of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 18-75 years; visible varicose veins in lower limbs; saphenofemoral junction reflux confirmed by doppler sonography. Exclusion criteria: inability to tolerate the supine position; inability to tolerate the procedure under local anaesthesia; uncontrolled local infection; concomitant ischemic symptoms in lower limbs; deep vein thrombosis; diabetes mellitus; use of any anticoagulants; any uncontrolled systemic disease such as terminal cancer patients or connective tissue diseases; lymphedema; pregnancy; history of thrombophilia; veins less than 3 mm or larger than 12 mm; tortuous vein

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

MeasureTime frame
Pulmonary embolism. Timepoint: days 1, 3, 7 and 28 after the operation. Method of measurement: physical exam and imaging studies if needed.;Return to work. Timepoint: days after the operation. Method of measurement: questionnare.

Primary

MeasureTime frame
Postoperative pain. Timepoint: days 1,3,7,14,28 after the operation. Method of measurement: with face pain scale.;Operative site erythema. Timepoint: days 1,3,7,14,28 after the operation. Method of measurement: physical exam.;Operative site echymosis. Timepoint: days 1,3,7,14,28 after the operation. Method of measurement: physical exam.;Operative site hematoma. Timepoint: days 1,3,7,14,28 after the operation. Method of measurement: physical exam.;Operative site infection. Timepoint: days 1,3,7,14,28 after the operation. Method of measurement: physical exam.;Skin burn in the operative site. Timepoint: days 1,3,7,14,28 after the operation. Method of measurement: physical exam.;Paresthesia in the operative site. Timepoint: days 1,3,7,14,28 after the operation. Method of measurement: physical exam.;Arterial damage in operative site. Timepoint: days 1,3,7,14,28 after the operation. Method of measurement: physical exam.;Hyperpigmentation at operative site. Timepoint: days 1,3,7,14,28 after the operation. Method of measurement: physical exam.;Deep vein thrombosis. Timepoint: days 1,3,7,14,28 after the operation. Method of measurement: physical exam and doppler sonography if needed.;Superficial vein phlebitis. Timepoint: days 1,3,7,14,28 after the operation. Method of measurement: physical exam.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzad Kakaei

Tabriz University Of Medical Sciences

fkakaei@yahoo.com+98 41 3334 1317

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026